The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1517
Triferic for Iron Replacement
The full article is available to subscribers Subscriber Login   

The FDA has approved ferric pyrophosphate citrate solution (Triferic – Rockwell Medical) to maintain hemoglobin concentrations in adults with hemodialysis-dependent chronic kidney disease. Triferic is the first iron replacement product that is added into the hemodialysis solution at each dialysis procedure.

IRON SUPPLEMENTATION — Iron deficiency anemia is common in patients with chronic kidney disease who require hemodialysis; contributing factors include gastrointestinal bleeding, blood draws, use of erythropoiesis-stimulating agents (ESAs), and hemodialysis itself. In these patients, IV iron is preferred over oral iron for supplementation because oral formulations are poorly absorbed.1 IV iron preparations approved for use in patients requiring hemodialysis include iron dextran (Dexferrum; INFeD), sodium ferric gluconate (Ferrlecit, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Triferic for Iron Replacement
Article code: 1517e
 Electronic, downloadable article - $25